Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical data trend for Zenlabs Ethica's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:530697 vs MCK, COR, CAH: Buyback Yield % Comparison
For the Medical Distribution subindustry, Zenlabs Ethica's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zenlabs Ethica Buyback Yield % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Zenlabs Ethica's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Zenlabs Ethica's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zenlabs Ethica (BOM:530697) has a Buyback Yield % of 0.00 as of Aug. 07, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Zenlabs Ethica and its competitors. According to the industry distribution chart, Zenlabs Ethica ranks #999999 out of 39 companies in the Medical Distribution industry.
Is Zenlabs Ethica's Buyback Yield % too high?
Zenlabs Ethica's current Buyback Yield % is 0.00. Based on the distribution chart, Zenlabs Ethica ranks #999999 out of 39 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Zenlabs Ethica has a GF Score™ of 55/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Zenlabs Ethica's Buyback Yield % compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Zenlabs Ethica ranks #999999 out of 39 companies for Buyback Yield %. This places Zenlabs Ethica in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Medical Distribution company?
A good Buyback Yield % depends on the Medical Distribution industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Zenlabs Ethica and its competitors. Zenlabs Ethica's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zenlabs Ethica stock overvalued right now?
Based on GuruFocus' analysis, Zenlabs Ethica (BOM:530697) is currently considered Fairly Valued. The stock's GF Value™ is ₹29.03, compared to a current price of ₹29.50 — trading 1.6% above its estimated fair value. The current Buyback Yield % is 0.00. Zenlabs Ethica's overall GF Score™ is 55/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Zenlabs Ethica (BOM:530697), the current Buyback Yield % is 0.00 as of Aug. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zenlabs Ethica (BOM:530697) Overvalued in 2026?
Based on GuruFocus' analysis, Zenlabs Ethica stock appears to be overvalued.
The current stock price of ₹29.50 is trading 1.6% above its estimated GF Value™ of ₹29.03.
GuruFocus considers Zenlabs Ethica to be Fairly Valued.
Key valuation signals for BOM:530697:
Buyback Yield %: 0.00
GF Value™: ₹29.03 vs. price of ₹29.50 (1.6% above fair value)
No single metric tells the full story. See the BOM:530697 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zenlabs Ethica Ltd is a pharmaceutical company engaged in the trading of pharmaceutical formulations. It manufactures and markets drugs which include Gastrointestinal disorders, anti-diabetics, anti-hypertensive drugs, anti-infective, soaps, and anti-Bacterial drugs, nutraceuticals, and others. In addition, The company offers more than 600 products across therapeutic segments.
55GF Score
Get the complete analysis for BOM:530697
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:530697 has been successfully added to your 
